Torsten Dahlén

Articles

Article: LANCET DIGITAL HEALTH. 2024;6(2):e105-e113
Using routine health-care data to search for unknown transfusion-transmitted disease: a nationwide, agnostic retrospective cohort study
Dahlen T; Zhao J; Busch MP; Edgren G
Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2023;330(10):941-950
Intracerebral Hemorrhage Among Blood Donors and Their Transfusion Recipients
Zhao J; Rostgaard K; Lauwers E; Dahlen T; Ostrowski SR; Erikstrup C; Pedersen OB; de Strooper B; Lemmens R; Hjalgrim H; Edgren G
Article: JOURNAL OF INTERNAL MEDICINE. 2023;293(3):398-402
A population-based, retrospective cohort study of the association between ABO blood group and risk of COVID-19
Dahlen T; Li H; Nyberg F; Edgren G
Article: JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2022;11(11):e024091
Neutrophil-to-Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries
Shahim B; Redfors B; Lindman BR; Chen S; Dahlen T; Nazif T; Kapadia S; Gertz ZM; Crowley AC; Li D; Thourani VH; Kodali SK; Zajarias A; Babaliaros VC; Guyton RA; Elmariah S; Herrmann HC; Cohen DJ; Mack MJ; Smith CR; Leon MB; George I
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2022;97(4):421-430
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study
Dahlen T; Edgren G; Ljungman P; Flygt H; Richter J; Olsson-Stromberg U; Wadenvik H; Dreimane A; Myhr-Eriksson K; Zhao J; Sjalander A; Hoglund M; Stenke L
Article: JOURNAL OF INTERNAL MEDICINE. 2022;291(1):95-100
The frequency of misattributed paternity in Sweden is low and decreasing: A nationwide cohort study
Dahlen T; Zhao J; Magnusson PKE; Pawitan Y; Lavrod J; Edgren G
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(5):915-921
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry
Flygt H; Sandin F; Dahlen T; Dremaine A; Lubking A; Markevarn B; Myhr-Eriksson K; Olsson K; Olsson-Stromberg U; Sjalander A; Soderlund S; Wennstrom L; Wadenvik H; Stenke L; Hoglund M; Richter J
Article: VOX SANGUINIS. 2021;116(5):581-590
Costs associated with transfusion therapy in patients with myelodysplastic syndromes in Sweden: a nationwide retrospective cohort study
Zhao J; Dahlen T; Edgren G
Article: ELIFE. 2021;10:e65658
An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk
Dahlen T; Clements M; Zhao J; Olsson ML; Edgren G
Article: TRANSFUSION. 2020;60(11):2591-2596
Risk of hematological malignancy in blood donors: A nationwide cohort study
Zhao J; Dahlen T; Brynolf A; Edgren G
Article: PLOS COMPUTATIONAL BIOLOGY. 2020;16(6):e1007927
Measurable health effects associated with the daylight saving time shift
Zhang H; Dahlen T; Khan A; Edgren G; Rzhetsky A
Article: NATURE COMMUNICATIONS. 2019;10(1):5508
Estimating heritability and genetic correlations from large health datasets in the absence of genetic data
Jia G; Li Y; Zhang H; Chattopadhyay I; Jensen AB; Blair DR; Davis L; Robinson PN; Dahlen T; Brunak S; Benson M; Edgren G; Cox NJ; Gao X; Rzhetsky A
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019;17(4):555-567
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
Hirt C; Iannazzo S; Chiroli S; McGarry LJ; le Coutre P; Stenke L; Dahlen T; Lipton JH
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(1):57-66
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
Soderlund S; Dahlen T; Sandin F; Olsson-Stromberg U; Creignou M; Dreimane A; Lubking A; Markevarn B; Sjalander A; Wadenvik H; Stenke L; Richter J; Hoglund M
Article: ANNALS OF INTERNAL MEDICINE. 2016;165(3):161-166
Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia A Population-Based Cohort Study
Dahlen T; Edgren G; Lambe M; Hoglund M; Bjorkholm M; Sandin F; Sjalander A; Richter J; Olsson-Stromberg U; Ohm L; Back M; Stenke L
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;96(2):175-180
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes
Dahlen T; Kalin M; Cederlund K; Nordlander A; Bjorkholm M; Ljungman P; Blennow O

All other publications

Letter: LEUKEMIA. 2023;37(5):1156-1159
The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study
Dahlen T; Flygt H; Lubking A; Olsson-Stromberg U; Wennstrom L; Dreimane A; Sjalander A; Leach S; Gisslen M; Li H; Hoglund M; Stenke L; Nyberg F
Doctoral thesis: 2023
Agnostic studies in epidemiology
Dahlén T

Articles

All other publications

Employments

Degrees and Education

Supervision

News from KI

Events from KI